MediciNova, Inc. (MNOV)

[Raffis]

Medicinova’s resources are jointly helping BioComo to produce a COVID-19 vaccine - - President Masayuki Fukumura, Mie prefecture, Japan; http://www.biocomo.jp/).

Medicinova said: President and Chief Executive Officer of MediciNova, Inc., commented, "Given the current global pandemic of COVID-19, we appreciate this very important opportunity to jointly develop a vaccine against SARS-CoV-2 with BC-PIV in collaboration with BioComo and Mie University. Previously, BioComo has been successful in developing vaccines against Ebola virus and RS virus with their BC-PIV technology, which made us confident that their technology will be successful for SARS-CoV-2 vaccines.”

BioComo said: Masayuki Fukumura, President of BioComo, commented, “We are very pleased to proceed with the co-development of a SARS-CoV-2 vaccine with MediciNova which has a proven track record of international clinical development for unmet medical needs.”

MediciNova has been granted exclusive worldwide development rights to use BC-PIV for SARS-CoV-2 vaccine development from BioComo and Mie University.